-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a number of MNCs (multinational corporations) have intensively released their 2021 financial reports.
During the sorting process, we focused on four indicators, namely: total revenue, R&D investment, revenue in China, and revenue from the top three blockbuster drugs
1.
1.
*The market value statistics time is Sunday, February 13, 2022
Among them, Johnson & Johnson holds the top spot in MNC with an annual revenue of $93.
From the perspective of growth rate, Pfizer will be the well-deserved big winner in 2021.
2.
2.
Sales in emerging markets grew by 89% year-on-year
Although AstraZeneca's sales growth in China is not high, only 4%, but among the six MNCs that have announced revenue in China, AstraZeneca China has the highest sales revenue
The highest sales revenue in China
3.
3.
5 companies account for more than 20% of R&D;
Blockbuster drugs are the current source of growth for companies, and the growth rate of blockbuster drug sales to a certain extent is expected to contribute to the drug's performance in the next year
Pfizer's Comirnaty Pfizer's Comirnaty AbbVie's Humira AbbVie's Humira
The strong are Hengqiang.
The growth rate is over 40% The growth rate is over 40%
4.
4.
New diseases without means of prevention, and new markets for therapeutic drugs
.
emerging markets along the “Belt and Road”,